• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography.血清素能通路在药物性瓣膜性心脏病中的作用及超声心动图诊断特征
J Am Soc Echocardiogr. 2009 Aug;22(8):883-9. doi: 10.1016/j.echo.2009.05.002. Epub 2009 Jun 23.
2
Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.瓣膜5-羟色胺5-HT(2B)受体在与芬氟拉明相关的心脏病中的可能作用。
Mol Pharmacol. 2000 Jan;57(1):75-81.
3
Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease.预测人类 5-羟色胺受体亚型 2B(5-HT2B)与心脏瓣膜病的计算机模拟研究。
Curr Top Med Chem. 2013;13(11):1353-62. doi: 10.2174/15680266113139990039.
4
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.帕金森病中多巴胺激动剂治疗引发的心脏瓣膜纤维化反应。
Lancet Neurol. 2007 Sep;6(9):826-9. doi: 10.1016/S1474-4422(07)70218-1.
5
Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis.利苏瑞ide,一种具有5-HT2B受体拮抗剂特性的多巴胺受体激动剂:缺乏心脏瓣膜病不良药物反应报告支持了5-HT2B受体激动在心脏瓣膜纤维化中起关键作用的概念。
Clin Neuropharmacol. 2006 Mar-Apr;29(2):80-6. doi: 10.1097/00002826-200603000-00005.
6
Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study.赛庚啶可预防大鼠培高利特诱导的瓣膜病:一项超声心动图和组织病理学研究。
Am J Physiol Heart Circ Physiol. 2009 Jun;296(6):H1940-8. doi: 10.1152/ajpheart.01177.2008. Epub 2009 Apr 3.
7
Drug-induced valvular heart disease: an update.药物性心脏瓣膜病:更新。
Arch Cardiovasc Dis. 2013 May;106(5):333-9. doi: 10.1016/j.acvd.2013.02.003. Epub 2013 Mar 22.
8
Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: a multicentre study.暴露于苯氟雷司的患者中选择性 5-羟色胺再摄取抑制剂治疗对心瓣膜的影响:一项多中心研究。
Arch Cardiovasc Dis. 2013 Jun-Jul;106(6-7):349-56. doi: 10.1016/j.acvd.2013.04.006. Epub 2013 May 31.
9
Valvular heart disease and the use of dopamine agonists for Parkinson's disease.心脏瓣膜病与多巴胺激动剂在帕金森病中的应用。
N Engl J Med. 2007 Jan 4;356(1):39-46. doi: 10.1056/NEJMoa054830.
10
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.严重多瓣膜心脏病:麦角衍生物多巴胺激动剂的一种新并发症。
Mov Disord. 2004 Jun;19(6):656-62. doi: 10.1002/mds.20201.

引用本文的文献

1
Case Report: unexpected cause of cyanosis in an infant after acute exposure to high altitude-severe tricuspid regurgitation secondary to tricuspid valve prolapse.病例报告:一名婴儿在急性暴露于高海拔地区后出现发绀的意外原因——三尖瓣脱垂继发严重三尖瓣反流。
Front Cardiovasc Med. 2024 Jun 12;11:1335218. doi: 10.3389/fcvm.2024.1335218. eCollection 2024.
2
Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.微量使用迷幻药与心脏纤维化和瓣膜病的风险:与已知的心脏毒素比较。
J Psychopharmacol. 2024 Mar;38(3):217-224. doi: 10.1177/02698811231225609. Epub 2024 Jan 12.
3
A Happy Patient Sheltering an Unhappy Valve: Serotonin Reuptake Inhibitor-Induced Tricuspid Valve Regurgitation.一位开心的患者却有着一个不开心的瓣膜:5-羟色胺再摄取抑制剂诱发的三尖瓣反流。
CASE (Phila). 2020 Dec 7;5(1):86-88. doi: 10.1016/j.case.2020.11.003. eCollection 2021 Feb.
4
The human endogenous metabolome as a pharmacology baseline for drug discovery.人类内源性代谢组作为药物发现的药理学基线。
Drug Discov Today. 2019 Sep;24(9):1806-1820. doi: 10.1016/j.drudis.2019.06.007. Epub 2019 Jun 19.
5
Antidepressants and Valvular Heart Disease: A Nested Case-Control Study in Taiwan.抗抑郁药与心脏瓣膜病:台湾地区一项巢式病例对照研究。
Medicine (Baltimore). 2016 Apr;95(14):e3172. doi: 10.1097/MD.0000000000003172.
6
Structure and function of serotonin G protein-coupled receptors.血清素G蛋白偶联受体的结构与功能
Pharmacol Ther. 2015 Jun;150:129-42. doi: 10.1016/j.pharmthera.2015.01.009. Epub 2015 Jan 17.
7
Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease.预测人类 5-羟色胺受体亚型 2B(5-HT2B)与心脏瓣膜病的计算机模拟研究。
Curr Top Med Chem. 2013;13(11):1353-62. doi: 10.2174/15680266113139990039.
8
Devices in the management of advanced, chronic heart failure.用于治疗晚期慢性心力衰竭的设备。
Nat Rev Cardiol. 2013 Feb;10(2):98-110. doi: 10.1038/nrcardio.2012.178. Epub 2012 Dec 11.
9
Use of antidepressant serotoninergic medications and cardiac valvulopathy: a nested case-control study in the health improvement network (THIN) database.使用抗抑郁药 5-羟色胺能药物与心脏瓣膜病:在健康改进网络(THIN)数据库中的巢式病例对照研究。
Br J Clin Pharmacol. 2012 Sep;74(3):536-44. doi: 10.1111/j.1365-2125.2012.04224.x.
10
Evaluation of [(11)C]metergoline as a PET radiotracer for 5HTR in nonhuman primates.评估[(11)C]麦角乙脲作为非人类灵长类动物 5HTR 的 PET 示踪剂。
Bioorg Med Chem. 2010 Nov 15;18(22):7739-45. doi: 10.1016/j.bmc.2010.04.039. Epub 2010 Apr 20.

本文引用的文献

1
Carcinoid heart disease.类癌性心脏病
Circulation. 2007 Dec 11;116(24):2860-5. doi: 10.1161/CIRCULATIONAHA.107.701367.
2
In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology.大鼠药物性瓣膜性心脏病的体内模型:用超声心动图显示培高利特诱导的瓣膜性心脏病及其与病理学的相关性。
Eur Heart J. 2007 Sep;28(17):2156-62. doi: 10.1093/eurheartj/ehm263. Epub 2007 Jul 18.
3
Valvular heart disease and the use of dopamine agonists for Parkinson's disease.心脏瓣膜病与多巴胺激动剂在帕金森病中的应用。
N Engl J Med. 2007 Jan 4;356(1):39-46. doi: 10.1056/NEJMoa054830.
4
Dopamine agonists and the risk of cardiac-valve regurgitation.多巴胺激动剂与心脏瓣膜反流风险
N Engl J Med. 2007 Jan 4;356(1):29-38. doi: 10.1056/NEJMoa062222.
5
Drugs and valvular heart disease.药物与心脏瓣膜病
N Engl J Med. 2007 Jan 4;356(1):6-9. doi: 10.1056/NEJMp068265.
6
5-hydroxytryptamine receptors in the human cardiovascular system.人类心血管系统中的5-羟色胺受体
Pharmacol Ther. 2006 Sep;111(3):674-706. doi: 10.1016/j.pharmthera.2005.12.004.
7
Assessment of patent foramen ovale in carcinoid heart disease.类癌性心脏病中卵圆孔未闭的评估
Am Heart J. 2006 May;151(5):1129.e1-6. doi: 10.1016/j.ahj.2006.02.019.
8
Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice.5-羟色胺转运体基因缺陷导致小鼠心脏纤维化和瓣膜病。
Circulation. 2006 Jan 3;113(1):81-9. doi: 10.1161/CIRCULATIONAHA.105.554667. Epub 2005 Dec 27.
9
Agonism at 5-HT2B receptors is not a class effect of the ergolines.5-HT2B受体激动作用并非麦角灵类药物的类效应。
Eur J Pharmacol. 2005 Apr 25;513(3):225-8. doi: 10.1016/j.ejphar.2005.03.010. Epub 2005 Apr 15.
10
Carcinoid heart disease: echocardiographic recognition and differential diagnosis.类癌性心脏病:超声心动图识别与鉴别诊断
Am Heart Hosp J. 2005 Spring;3(2):132-5. doi: 10.1111/j.1541-9215.2005.04044.x.

血清素能通路在药物性瓣膜性心脏病中的作用及超声心动图诊断特征

Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography.

作者信息

Smith Sakima A, Waggoner Alan D, de las Fuentes Lisa, Davila-Roman Victor G

机构信息

Cardiovascular Imaging and Clinical Research Core Laboratory, Cardiovascular Division, Washington University School of Medicine, St Louis, Missouri 63110, USA.

出版信息

J Am Soc Echocardiogr. 2009 Aug;22(8):883-9. doi: 10.1016/j.echo.2009.05.002. Epub 2009 Jun 23.

DOI:10.1016/j.echo.2009.05.002
PMID:19553085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3808845/
Abstract

Serotonin plays a significant role in the development of carcinoid heart disease, which primarily leads to fibrosis and contraction of right-sided heart valves. Recently, strong evidence has emerged that the use of specific drug classes, such as ergot alkaloids (for migraine headaches), 5-hydroxytryptamine (5-HT or serotonin) uptake regulators or inhibitors (for weight reduction), and ergot-derived dopamine agonists (for Parkinson's disease), can result in left-sided heart valve damage that resembles carcinoid heart disease. Recent studies have suggested that both right-sided and left-sided drug-induced heart valve disease involves increased serotoninergic activity and in particular activation of the 5-HT receptors, including the 5-HT2B receptor subtype, which mediate many of the central and peripheral functions of serotonin. G-proteins that inhibit adenylate cyclase activity mediate the activity of the 5-HT2B receptor subunit, which is widely expressed in a variety of tissues, including liver, lung, heart, and coronary and pulmonary arteries; it has also been reported in embryonic mouse heart, particularly on mouse heart valve leaflets. In this review, the authors discuss the salient features of serotoninergic manifestations of both carcinoid heart disease and drug-induced cardiac valvulopathy, with an emphasis on echocardiographic diagnosis.

摘要

血清素在类癌性心脏病的发展中起重要作用,类癌性心脏病主要导致右侧心脏瓣膜纤维化和挛缩。最近,有确凿证据表明,使用特定药物类别,如麦角生物碱(用于偏头痛)、5-羟色胺(5-HT或血清素)摄取调节剂或抑制剂(用于减肥)以及麦角衍生的多巴胺激动剂(用于帕金森病),可导致类似于类癌性心脏病的左侧心脏瓣膜损伤。最近的研究表明,右侧和左侧药物性心脏瓣膜病均涉及血清素能活性增加,特别是5-HT受体的激活,包括5-HT2B受体亚型,这些受体介导血清素的许多中枢和外周功能。抑制腺苷酸环化酶活性的G蛋白介导5-HT2B受体亚基的活性,该亚基在包括肝脏、肺、心脏以及冠状动脉和肺动脉在内的多种组织中广泛表达;在胚胎小鼠心脏中也有报道,特别是在小鼠心脏瓣膜小叶上。在这篇综述中,作者讨论了类癌性心脏病和药物性心脏瓣膜病血清素能表现的显著特征,重点是超声心动图诊断。